Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Ruzaika Cader
ResearcherPublications, citations & collaboration network
Ruzaika Cader is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 3 works, 13 citations, an h-index of 2 and an i10-index of 0.
3
Works
13
Citations
2
h-index
0
i10-index
IDs:OpenAlex
How has Ruzaika Cader's publication output changed over time?
ScholarIQpublication output · 2024
3
2024
What are the most-cited papers on Ruzaika Cader?
ScholarIQmost cited works
A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)
Lisa Willcocks, Wendi Qian, Ruzaika Cader, Katrina Gatley, Hira Siddiqui, Endurance Tabebisong, Karlena Champion, Andreas Kronbichler, Liz Lightstone, David Jayne, Edward Wilson, Megan Griffith
BMC Nephrology. 20247 CitationsOPEN ACCESS
Advances in primary glomerulonephritis
B. Ellison, Ruzaika Cader, Lisa Willcocks
British Journal of Hospital Medicine. 20246 CitationsOPEN ACCESS
Study Protocol: The Use of Rituximab in Nephrotic Glomerulonephritis (TURING)
Lisa Willcocks, Wendi Qian, Ruzaika Cader, Katrina Gatley, Hira Siddiqui, Endurance Tabebisong, Karlena Champion, Andreas Kronbichler, Liz Lightstone, David Jayne, Edward Wilson, Megan Griffith
Research Square. 20240 CitationsOPEN ACCESS
Related on ScholarIQ
University of Cambridge
Institution
A randomised, two-arm (1:1 ratio), double blind, placebo controlled phase III trial to assess the efficacy, safety, cost and cost-effectiveness of Rituximab in treating de novo or relapsing NS in patients with MCD/FSGS (TURING)
Paper
Advances in primary glomerulonephritis
Paper
Study Protocol: The Use of Rituximab in Nephrotic Glomerulonephritis (TURING)
Paper
Renal Diseases and Glomerulopathies
Topic
Systemic Lupus Erythematosus Research
Topic